

# Come Lepage

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2017672/publications.pdf>

Version: 2024-02-01

34  
papers

585  
citations

858243

12  
h-index

721071

23  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1169  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. <i>Digestive and Liver Disease</i> , 2022, 54, 324-330.	0.4	5
2	Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. <i>Cancers</i> , 2022, 14, 1675.	1.7	3
3	Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2022, , .	1.9	2
4	Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients: A pooled analysis of three adjuvant trials. <i>European Journal of Cancer</i> , 2022, 166, 100-111.	1.3	13
5	Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101464.	0.7	9
6	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021, 53, 318-323.	0.4	14
7	Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. <i>Colorectal Disease</i> , 2021, 23, 1357-1369.	0.7	23
8	Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences. <i>Digestive and Liver Disease</i> , 2021, 53, 1492-1498.	0.4	5
9	What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 776-784.	0.4	2
10	FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. <i>Digestive and Liver Disease</i> , 2021, 53, 824-829.	0.4	9
11	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3242-3250.	0.8	35
12	Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1034-1040.	0.4	3
13	Chemotherapy of metastatic colon cancer in France: A population-based study. <i>Digestive and Liver Disease</i> , 2021, 53, 1334-1342.	0.4	2
14	Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1255-1262.	0.5	12
15	Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA: The CIRCULATE-PRODIGE 70 trial. <i>Digestive and Liver Disease</i> , 2020, 52, 730-733.	0.4	18
16	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , 2020, 19, 285-290.	1.0	5
17	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). <i>European Journal of Cancer</i> , 2020, 136, 25-34.	1.3	6
18	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD,) Tj ETQq1.4 0.784834 rgBT (C	1.4	4
20	COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Digestive and Liver Disease, 2020, 52, 597-603.	0.4	37
21	Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. European Journal of Cancer, 2019, 123, 92-100.	1.3	3
22	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). Journal of Clinical Oncology, 2018, 36, 674-681.	0.8	70
23	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. European Journal of Cancer, 2018, 98, 1-9.	1.3	30
24	Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S48-S55.	0.6	14
25	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Digestive and Liver Disease, 2017, 49, 568-571.	0.4	3
26	Copy number variations in <i>DCC</i> 18q and <i>ERBB2</i> 17q are associated with disease-free survival in microsatellite stable colon cancer. International Journal of Cancer, 2017, 140, 1653-1661.	2.3	10
27	<i>HSP110</i> T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. Journal of Medical Genetics, 2016, 53, 377-384.	1.5	46
28	Conditional net survival: Relevant prognostic information for colorectal cancer survivors. A French population-based study. Digestive and Liver Disease, 2015, 47, 597-601.	0.4	13
29	Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer. Digestive and Liver Disease, 2014, 46, 1121-1125.	0.4	19
30	Immunochemical faecal occult blood tests for colorectal cancer screening: No time to lose. Digestive and Liver Disease, 2014, 46, 30-31.	0.4	1
31	Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. Digestive and Liver Disease, 2014, 46, 358-362.	0.4	15
32	Adjuvant treatments for gastric cancer: From practice guidelines to clinical practice. Digestive and Liver Disease, 2014, 46, 72-75.	0.4	10
33	Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: A French population-based study. Digestive and Liver Disease, 2014, 46, 854-858.	0.4	46
34	Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert's disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.. Journal of Clinical Oncology, 2013, 31, 3614-3614.	0.8	2